BRKR
Bruker Corporation NASDAQ Listed Aug 4, 2000$57.23
+4.57%
vs $54.73
Mkt Cap $8.7B
52w Low $28.53
79.7% of range
52w High $64.54
50d MA $45.95
200d MA $41.85
P/E (TTM)
-381.5x
EV/EBITDA
35.1x
P/B
3.5x
Debt/Equity
0.8x
ROE
-0.4%
P/FCF
200.6x
RSI (14)
46.60
ATR (14)
$3.04
Beta
1.20
50d MA
$45.95
200d MA
$41.85
Avg Volume
2.9M
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
40 Manning Road · Billerica, MA 01821 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | TNS | 0.23 | 0.31 | +34.8% | 42.30 | +1.1% | +3.4% | +1.0% | -2.0% | +3.4% | -2.0% | — |
| Feb 12, 2026 | TNS | 0.65 | 0.59 | -9.2% | 37.51 | -1.5% | -2.7% | +4.4% | +4.3% | -2.5% | -1.2% | — |
| Nov 3, 2025 | TNS | 0.33 | 0.60 | +81.8% | 38.71 | -0.2% | +4.3% | -0.4% | -2.2% | +1.6% | +2.1% | — |
| Aug 4, 2025 | TNS | 0.33 | 0.32 | -3.0% | 34.72 | +0.2% | -7.6% | -4.4% | +1.6% | -2.3% | +1.2% | — |
| May 7, 2025 | TNS | 0.46 | 0.47 | +2.2% | 40.76 | -0.6% | -0.6% | -7.4% | +7.3% | -3.8% | -4.9% | — |
| Feb 13, 2025 | TNS | 0.75 | 0.76 | +1.3% | 51.15 | +0.7% | -2.2% | +1.4% | +1.6% | +2.7% | -4.0% | — |
| Nov 5, 2024 | TNS | 0.61 | 0.60 | -1.6% | 61.34 | +0.7% | -3.8% | +2.6% | -4.6% | -1.9% | -1.1% | — |
| Aug 6, 2024 | TNS | 0.52 | 0.52 | +0.0% | 62.16 | +1.9% | -3.0% | +5.0% | -2.1% | -2.5% | +1.6% | — |
| May 2, 2024 | TNS | 0.46 | 0.53 | +15.2% | 70.09 | +0.9% | -0.1% | +3.5% | +2.5% | -0.8% | +3.4% | — |
| Feb 13, 2024 | TNS | 0.65 | 0.70 | +7.7% | 76.79 | +2.6% | +4.2% | +0.1% | +2.1% | -0.9% | +1.0% | — |
| Nov 2, 2023 | TNS | 0.63 | 0.74 | +17.5% | 56.41 | +0.2% | +4.3% | -4.5% | +3.8% | -0.9% | -0.8% | — |
| Aug 3, 2023 | TNS | 0.49 | 0.50 | +2.0% | 67.52 | -0.7% | -1.9% | +0.8% | -1.8% | +0.2% | +1.0% | — |
| May 4, 2023 | BMO | 0.55 | 0.64 | +16.4% | 81.58 | +0.6% | -3.7% | -1.8% | -1.2% | -0.6% | +1.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 2 | Wolfe Research | Reiterates | Peer Perform | — | $58.44 | $57.41 | -1.8% | -1.9% | +9.4% | -4.4% | -6.0% | -0.2% |
| Apr 15 | Barclays | Maintains | Overweight → Overweight | — | $39.90 | $39.90 | +0.0% | -1.1% | -1.4% | +4.5% | +1.0% | -2.5% |
| Apr 14 | Barclays | Maintains | Overweight → Overweight | — | $39.05 | $39.54 | +1.3% | +2.2% | -1.1% | -1.4% | +4.5% | +1.0% |
| Mar 30 | Guggenheim | Maintains | Buy → Buy | — | $33.72 | $33.41 | -0.9% | +1.7% | +5.3% | -0.1% | +1.9% | -0.1% |
| Feb 13 | TD Cowen | Maintains | Hold → Hold | — | $37.51 | $36.94 | -1.5% | -2.7% | +4.4% | +4.3% | -2.5% | -1.2% |
| Feb 13 | Goldman Sachs | Maintains | Sell → Sell | — | $37.51 | $36.94 | -1.5% | -2.7% | +4.4% | +4.3% | -2.5% | -1.2% |
| Feb 13 | Citigroup | Maintains | Neutral → Neutral | — | $37.51 | $36.94 | -1.5% | -2.7% | +4.4% | +4.3% | -2.5% | -1.2% |
| Feb 13 | Barclays | Maintains | Overweight → Overweight | — | $37.51 | $36.94 | -1.5% | -2.7% | +4.4% | +4.3% | -2.5% | -1.2% |
| Jan 26 | Guggenheim | Maintains | Buy → Buy | — | $50.33 | $49.75 | -1.2% | -3.8% | -1.6% | -2.3% | -5.0% | +0.1% |
| Jan 16 | Citigroup | Maintains | Neutral → Neutral | — | $49.46 | $49.45 | -0.0% | -2.2% | +3.0% | +4.2% | +0.3% | -3.4% |
| Jan 7 | TD Cowen | Maintains | Hold → Hold | — | $52.67 | $52.17 | -0.9% | +0.6% | -1.0% | +3.8% | -1.9% | -4.7% |
| Jan 5 | Guggenheim | Maintains | Buy → Buy | — | $48.11 | $48.06 | -0.1% | +6.5% | +2.8% | +0.6% | -1.0% | +3.8% |
| Dec 15 | Wells Fargo | Maintains | Overweight → Overweight | — | $45.13 | $46.34 | +2.7% | +1.2% | -1.6% | -1.2% | +0.6% | +4.1% |
| Dec 15 | BofA Securities | Maintains | Buy → Buy | — | $45.13 | $46.34 | +2.7% | +1.2% | -1.6% | -1.2% | +0.6% | +4.1% |
| Dec 15 | JP Morgan | Maintains | Overweight → Overweight | — | $45.13 | $46.34 | +2.7% | +1.2% | -1.6% | -1.2% | +0.6% | +4.1% |
| Dec 15 | Barclays | Maintains | Overweight → Overweight | — | $45.13 | $46.34 | +2.7% | +1.2% | -1.6% | -1.2% | +0.6% | +4.1% |
| Dec 10 | Wolfe Research | Upgrade | Peer Perform → Outperform | — | $45.36 | $46.83 | +3.2% | +3.4% | -1.2% | -2.7% | +1.2% | -1.6% |
| Nov 5 | Wells Fargo | Maintains | Overweight → Overweight | — | $40.38 | $39.45 | -2.3% | -0.4% | -2.2% | +1.6% | +2.1% | +2.3% |
| Nov 4 | Barclays | Maintains | Overweight → Overweight | — | $38.71 | $38.63 | -0.2% | +4.3% | -0.4% | -2.2% | +1.6% | +2.1% |
| Nov 4 | TD Cowen | Maintains | Hold → Hold | — | $38.71 | $38.63 | -0.2% | +4.3% | -0.4% | -2.2% | +1.6% | +2.1% |
| Nov 4 | UBS | Maintains | Neutral → Neutral | — | $38.71 | $38.63 | -0.2% | +4.3% | -0.4% | -2.2% | +1.6% | +2.1% |
| Oct 2 | Barclays | Maintains | Overweight → Overweight | — | $34.72 | $34.86 | +0.4% | +0.3% | +6.2% | -1.4% | -5.2% | +0.2% |
| Aug 5 | Wells Fargo | Maintains | Overweight → Overweight | — | $34.72 | $34.80 | +0.2% | -7.6% | -4.4% | +1.6% | -2.3% | +1.2% |
| Aug 5 | Stifel | Maintains | Hold → Hold | — | $34.72 | $34.80 | +0.2% | -7.6% | -4.4% | +1.6% | -2.3% | +1.2% |
| Aug 4 | Barclays | Maintains | Overweight → Overweight | — | $37.99 | $34.13 | -10.2% | -8.6% | -7.6% | -4.4% | +1.6% | -2.3% |
| Aug 4 | Citigroup | Maintains | Neutral → Neutral | — | $37.99 | $34.13 | -10.2% | -8.6% | -7.6% | -4.4% | +1.6% | -2.3% |
| Aug 4 | Jefferies | Maintains | Buy → Buy | — | $37.99 | $34.13 | -10.2% | -8.6% | -7.6% | -4.4% | +1.6% | -2.3% |
| Jun 26 | BofA Securities | Maintains | Buy → Buy | — | $40.93 | $40.94 | +0.0% | +3.1% | -0.9% | -1.4% | +1.7% | +1.3% |
| May 22 | Citigroup | Downgrade | Buy → Neutral | — | $36.45 | $35.75 | -1.9% | -0.3% | -2.3% | +4.6% | -0.5% | +0.8% |
| May 8 | UBS | Maintains | Neutral → Neutral | — | $40.76 | $40.51 | -0.6% | -0.6% | -7.4% | +7.3% | -3.8% | -4.9% |
| May 8 | Barclays | Maintains | Overweight → Overweight | — | $40.76 | $40.51 | -0.6% | -0.6% | -7.4% | +7.3% | -3.8% | -4.9% |
| May 8 | Goldman Sachs | Maintains | Neutral → Neutral | — | $40.76 | $40.51 | -0.6% | -0.6% | -7.4% | +7.3% | -3.8% | -4.9% |
| May 8 | Stifel | Maintains | Hold → Hold | — | $40.76 | $40.51 | -0.6% | -0.6% | -7.4% | +7.3% | -3.8% | -4.9% |
| Apr 17 | Wells Fargo | Maintains | Overweight → Overweight | — | $37.74 | $37.11 | -1.7% | -3.9% | -0.8% | +2.7% | +2.5% | +2.9% |
| Apr 10 | Barclays | Maintains | Overweight → Overweight | — | $41.19 | $40.02 | -2.8% | -7.6% | +1.8% | +3.1% | -3.9% | -1.8% |
| Apr 7 | Citigroup | Maintains | Buy → Buy | — | $36.46 | $35.55 | -2.5% | +6.1% | -6.0% | +13.3% | -7.6% | +1.8% |
| Feb 24 | Guggenheim | Maintains | Buy → Buy | — | $50.82 | $50.45 | -0.7% | +2.1% | -1.7% | -1.0% | -5.4% | -1.1% |
| Feb 14 | Barclays | Maintains | Overweight → Overweight | — | $51.15 | $51.50 | +0.7% | -2.2% | +1.4% | +1.6% | +2.7% | -4.0% |
| Feb 14 | Stifel | Maintains | Hold → Hold | — | $51.15 | $51.50 | +0.7% | -2.2% | +1.4% | +1.6% | +2.7% | -4.0% |
| Feb 10 | Barclays | Maintains | Overweight → Overweight | — | $55.59 | $54.00 | -2.9% | -8.0% | -0.9% | +2.0% | -1.0% | -2.2% |
| Jan 17 | Guggenheim | Maintains | Buy → Buy | — | $59.01 | $59.58 | +1.0% | -3.6% | +5.6% | +0.1% | -3.2% | -1.5% |
| Dec 13 | BofA Securities | Maintains | Buy → Buy | — | $58.52 | $58.57 | +0.1% | -1.4% | -1.0% | +1.1% | -4.2% | -0.2% |
| Dec 5 | Goldman Sachs | Upgrade | Sell → Neutral | — | $59.50 | $59.95 | +0.8% | -1.7% | +0.8% | +4.2% | -2.4% | -0.6% |
| Nov 6 | TD Cowen | Maintains | Hold → Hold | — | $61.34 | $61.80 | +0.7% | -3.8% | +2.6% | -4.6% | -1.9% | -1.1% |
| Nov 6 | Barclays | Maintains | Overweight → Overweight | — | $61.34 | $61.80 | +0.7% | -3.8% | +2.6% | -4.6% | -1.9% | -1.1% |
| Nov 6 | Wells Fargo | Maintains | Overweight → Overweight | — | $61.34 | $61.80 | +0.7% | -3.8% | +2.6% | -4.6% | -1.9% | -1.1% |
| Nov 6 | Citigroup | Maintains | Buy → Buy | — | $61.34 | $61.80 | +0.7% | -3.8% | +2.6% | -4.6% | -1.9% | -1.1% |
| Sep 30 | Wolfe Research | Downgrade | Outperform → Peer Perform | — | $70.67 | $69.46 | -1.7% | -2.3% | -3.3% | +1.0% | -2.5% | +1.8% |
| Aug 7 | TD Cowen | Maintains | Hold → Hold | — | $62.16 | $63.31 | +1.9% | -3.0% | +5.0% | -2.1% | -2.5% | +1.6% |
| Jul 10 | Citigroup | Maintains | Buy → Buy | — | $61.21 | $61.55 | +0.6% | +0.1% | +4.0% | +1.6% | -2.1% | +4.5% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | Munch Mark | EXEC VP&PRES BRUKER NANO INC. | Sell | 2,000 | $54.76 | $110K | 128,443 | -1.92% | — |
| May 15, 2026 | Munch Mark | EXEC VP&PRES BRUKER NANO INC. | Sell | 2,000 | $43.90 | $88K | 128,443 | -0.37% | +2.69% |
8-K · 2.02
!! High
Bruker Corporation -- 8-K 2.02: Earnings Results
Bruker Corporation reported first-quarter 2026 earnings results, providing investors with updated financial performance and operational metrics for the three-month period ended March 31, 2026.
May 6
8-K · 5.02
!!! Very High
Mesa Laboratories Inc -- 8-K 5.02: Executive Change
Mesa Laboratories appoints Dr. Siddhartha Kadia as President following Owens' resignation, signaling leadership transition that investors should monitor for strategic direction changes.
Mar 9
8-K · 5.02
!!! Very High
Bruker Corporation -- 8-K 5.02: Executive Change
Jack Phillips resigned from Bruker Corporation's board, creating a vacancy in the Class II director position that requires replacement.
Feb 20
8-K
Bruker Corporation -- 8-K Filing
Bruker Corporation exceeded fourth-quarter revenue expectations despite 2025 headwinds from academic funding cuts, tariffs, and currency challenges, signaling resilience in its core business.
Feb 12
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Orbis Allan Gray Ltd | 17,940,076 | $648M | Added | Mar 2026 |
| 2 | Fmr Llc | 16,101,803 | $582M | Added | Mar 2026 |
| 3 | Vanguard Portfolio Management Llc | 4,855,915 | $175M | New | Mar 2026 |
| 4 | Vanguard Capital Management Llc | 4,817,076 | $174M | New | Mar 2026 |
| 5 | Morgan Stanley | 3,353,680 | $158M | Reduced | Dec 2025 |
| 6 | Franklin Resources Inc | 2,919,177 | $105M | Added | Mar 2026 |
| 7 | London Co Of Virginia | 2,584,029 | $93M | Reduced | Mar 2026 |
| 8 | M&g Plc | 1,655,672 | $60M | Added | Mar 2026 |
| 9 | Samlyn Capital, Llc | 1,540,049 | $56M | Added | Mar 2026 |
| 10 | First Trust Advisors Lp | 1,493,053 | $54M | Added | Mar 2026 |
| 11 | Millennium Management | 1,485,089 | $54M | Reduced | Mar 2026 |
| 12 | Artisan Partners Limited Partnership | 1,427,781 | $52M | Added | Mar 2026 |
| 13 | Aqr Capital Management Llc | 1,292,899 | $46M | Added | Mar 2026 |
| 14 | Capital Research Global Investors | 1,069,067 | $39M | New | Mar 2026 |
| 15 | Northern Trust Corp | 973,122 | $35M | Added | Mar 2026 |
| 16 | Point72 Asset Management | 952,873 | $34M | Reduced | Mar 2026 |
| 17 | Bank Of America Corp /de/ | 933,596 | $34M | Reduced | Mar 2026 |
| 18 | Old West Investment Management, Llc | 684,770 | $32M | Added | Dec 2025 |
| 19 | Primecap Management Co/ca/ | 857,600 | $31M | Added | Mar 2026 |
| 20 | Ubs Group Ag | 809,896 | $29M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$8.71B
Enterprise Value
$10.08B
P/E (TTM)
-381.53x
Forward P/E
27.07x
PEG Ratio
6.94x
P/B
3.46x
P/S
2.53x
P/FCF
200.64x
EV/EBITDA
35.07x
Shares Out
151.8M
Financials (TTM)
Revenue
$3.44B
Net Income
-$8.6M
EBITDA
$287.5M
Free Cash Flow
$43.3M
Op Cash Flow
$134.1M
EPS Basic
$-0.15
EPS Diluted
$-0.15
EPS Forward
$2.11
Gross Margin
45.6%
Op Margin
6.3%
Net Margin
-0.2%
Balance Sheet
Total Assets
$6.24B
Total Liab.
$3.73B
Total Equity
$2.51B
Cash
$298.8M
LT Debt
$1.69B
Book Value/Sh
$16.54
Debt/Equity
0.83x
Current Ratio
1.73
Quick Ratio
0.87
Returns & Growth
ROE
-0.4%
ROA
-0.1%
ROIC
-1.7%
Rev Growth YoY
+2.1%
EPS Growth YoY
-119.7%
Price Returns
2W
+33.4%
1M
+60.4%
3M
+46.8%
6M
+20.7%
12M
+60.5%
Technicals
52W High
$64.54
52W Low
$28.53
50d MA
$45.95
200d MA
$41.85
RSI (14)
46.60
ATR (14)
$3.04
Beta
1.20
Avg Volume
2.9M
Dividends
Div Rate
$0.15
Div Yield
0.4%
Frequency
4
Ex-Div Date
Mar 23, 2026
Analyst Price Targets
Consensus
$52.13
High
$60.00
Low
$35.00
Median
$52.50
Data updated apr 24, 2026 10:48pm
· Source: financialmodelingprep.com